| Literature DB >> 31467593 |
Guilherme Braga Lamacchia1, Fernando Korkes1, Willy Baccaglini1, Luiz Gustavo Miolaro de Mello2, Marcelo Szwarc1, Marcos Tobias-Machado1.
Abstract
BACKGROUND: The incidence of urinary lithiasis has been increasing in recent decades at all ages, including the elderly. In parallel, the world population is aging and there is a paucity of data on treatment of urinary stones in very elderly people. Our main objective was to evaluate the effects of extracorporeal shockwave lithotripsy (ESWL) in patients older than 75 years, and the characteristics of this population. Complications and mortality rates after this procedure in octogenarians were also described.Entities:
Keywords: aged 80 and over; kidney; lithiasis; lithotripsy; therapeutics
Year: 2019 PMID: 31467593 PMCID: PMC6704411 DOI: 10.1177/1756287219870412
Source DB: PubMed Journal: Ther Adv Urol ISSN: 1756-2872
Demographic characteristics of all patients and clinical information of the urinary calculi.
| ⩾75 year | <75 year |
| |
|---|---|---|---|
| 78 (75–90) | 42.1 (3–74) | <0.001 | |
|
| 604 | 53,542 | |
|
| 0.915 | ||
| Male | 53 (55.2%) | 19,043 (56.3%) | |
| Female | 43 (44.8%) | 14,799 (43.7%) | |
|
| 0.036 | ||
| Right | 273 (45.2%) | 26,533 (49.6%) | |
| Left | 331 (54.8%) | 27,009 (50.4%) | |
|
| <0.001 | ||
| First | 502 (83.1%) | 47,366 (88.5%) | |
| Reapplication | 102 (16.9%) | 6176 (11.5%) | |
|
| 0.58 | ||
| Mean (SD) | 2688.5 (779.1) | 2650.8 (919.9) | |
| <0.001 | |||
| Mean (SD) | 10.1 (4.48) | 8.5 (4.0) | |
|
| 0.98 | ||
| Renal | 517 (85.6%) | 46,866 (87.5%) | |
| Ureteral | 72 (11.2%) | 6542 (12.2%) | |
| Bladder | 15 (0.2%) | 127 (0.3%) |
SD, standard deviation.
Figure 1.Distribution of 33,938 patients who underwent ESWL according to age group.
ESWL, extracorporeal shockwave lithotripsy.
Figure 2.Kaplan–Meyer’s survival curve of octogenarians who underwent ESWL.
ESWL, extracorporeal shockwave lithotripsy.
Death causes, comorbidities, CCI, medications used and complications of ESWL according to Clavien–Dindo index among octogenarians.
| Cause of death |
| Mean interval between treatment and death (months) | ||
|---|---|---|---|---|
| Malignancies | 8 | 53 | ||
| Cardiovascular | 5 | 44 | ||
| Lung | 3 | 61 | ||
| Stroke | 2 | 114 | ||
| Others | 2 | 87 | ||
| Unknown | 3 | 52 | ||
|
|
| |||
| Cardiopathy | 11 (24.4%) | |||
| Pneumopathy | 4 (8.9%) | |||
| Arterial Hypertension | 30 (66.7%) | |||
| Malignancies | 5 (11.1%) | |||
| Prostate Pathologies | 6 (25% of men) | |||
| Neurological Pathologies | 10 (22.2%) | |||
| Bone Pathologies | 10 (22.2%) | |||
| Dyslipidemia | 12 (26.7%) | |||
| Diabetes | 8 (18.2%) | |||
|
|
|
|
| |
| 3 | 21 (47.7%) | I | 1 | |
| 4 | 10 (22.7%) | II | 0 | |
| 5 | 6 (13.6%) | IIIA | 3 | |
| 6 | 6 (13.6%) | IIIB | 0 | |
| 7 | 1 (2.3%) | IVA | 0 | |
|
|
| |||
| Antihypertensive | 30 (66.7%) | |||
| Antidiabetic | 9 (20.0%) | |||
| Hypolipemiant | 13 (28.9%) | |||
| Insulin | 0 | |||
| Antiplatelet | 8 (17.8%) | |||
| Prostate | 3 (12.5% of men – 6.7% total) | |||
| Anticoagulants | 1 (2.2%) | |||
| Neurological | 7 (15.6%) | |||
| Supplements | 5 (11.1%) | |||
| Antiarrhythimic or Cardiologic | 3 (6.8%) | |||
CCI,Charlson comorbidity index; ESWL, extracorporeal shockwave lithotripsy.